文献速递艾滋病与性传播感染

接受蛋白酶抑制剂单药治疗的人类免疫缺陷病毒阳性患者的脑灌注、区域体积与认知功能

Brain Perfusion, Regional Volumes, and Cognitive Function in Human Immunodeficiency Virus-positive Patients Treated With Protease Inhibitor Monotherapy.
PubMed 文献 · Clin Infect Dis · 2019-01-01

本研究在随机HIV治疗策略试验结束后,对37例持续三联治疗和39例蛋白酶抑制剂单药治疗(PIM)的患者进行认知评估和脑磁共振成像。结果显示两组在脑血流量或区域体积上无差异;无论治疗分组,精细运动表现较差与尾状核、丘脑、额叶皮层、枕叶皮层和扣带回皮层脑血流量较低相关,并与幕上白质体积较小相关。结论认为PIM不增加额外神经损伤风险。

要点

  • PIM组与持续三联治疗组在脑血流量或区域脑体积上无差异。
  • 精细运动表现较差与多个脑区低灌注及幕上白质体积较小相关。
  • PIM不增加额外神经损伤风险。

核心结论

  • PIM与三联治疗相比不增加额外神经损伤风险。
  • 精细运动损害、灰质低灌注与白质体积丢失之间存在相关性。

研究设计与样本

  • 在随机HIV治疗策略试验最终访视后进行认知评估和脑磁共振成像。
  • 参与者入组时接受三联治疗且病毒学抑制,随访3-5年。
  • 研究纳入37例随机接受持续三联治疗的患者和39例随机接受PIM的患者。

主要发现

  • 两组在脑血流量或区域体积上无差异。
  • 无论治疗分组,精细运动表现较差与尾状核(P = .01)、丘脑(P = .04)、额叶皮层(P = .01)、枕叶皮层(P = .004)和扣带回皮层(P = .02)脑血流量较低相关。
  • 精细运动表现较差与幕上白质体积较小相关(颅内体积每减少1%,Z评分下降0.16,95%置信区间0.02-0.29;P = .023)。
  • 平均年龄48.1岁(标准差8.6岁),63例男性(83%),64例白人(84%)。
  • 抗逆转录病毒治疗经验中位数8.1年(四分位距6.4,10.8),CD4+计数中位数640个细胞/mm3(四分位距490,780)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Protease inhibitor monotherapy (PIM) for human immunodeficiency virus (HIV) may exert suboptimal viral control in the central nervous system. We determined whether cerebral blood flow (CBF) and regional brain volumes were associated with PIM, and whether specific cognitive domains were associated with imaging biomarkers. METHODS: Cognitive assessments and brain magnetic resonance imaging were performed after the final visit of a randomized HIV-treatment strategy trial. Participants were virologically suppressed on triple therapy at trial entry and followed for 3-5 years. We studied 37 patients randomized to ongoing triple therapy and 39 randomized to PIM. Resting CBF and normalized volumes were calculated for brain regions of interest, and correlated with treatment strategy and neuropsychological performance. RESULTS: Mean age was 48.1 years (standard deviation 8.6 years), 63 male (83%), and 64 white (84%). Participants had median 8.1 years (interquartile range 6.4, 10.8) of antiretroviral therapy experience and CD4+ counts of median 640 cells/mm3 (interquartile range 490, 780). We found no difference between treatment arms in CBF or regional volumes. Regardless of treatment arm, poorer fine motor performance correlated with lower CBF in the caudate nucleus (P = .01), thalamus (P = .04), frontal cortex (P = .01), occipital cortex (P = .004), and cingulate cortex (P = .02), and was associated with smaller supratentorial white matter volume (decrease of 0.16 in Z-score per -1% of intracranial volume, 95% confidence interval 0.02-0.29; P = .023). CONCLUSIONS: PIM does not confer an additional risk of neurological injury compared with triple therapy. There were correlations between fine motor impairment, grey matter hypoperfusion, and white matter volume loss. CLINICAL TRIALS REGISTRATION: ISRCTN-04857074.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Haddow LJ, Godi C, Sokolska M, et al. Brain Perfusion, Regional Volumes, and Cognitive Function in Human Immunodeficiency Virus-positive Patients Treated With Protease Inhibitor Monotherapy. Clin Infect Dis. 2019. PMID: 30084882. doi:10.1093/cid/ciy617

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。